Biocryst Pharmaceuticals Inc
BCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882796
No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.61B in total; no superinvestor holds it.
Holders of 5% or more of BCRX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Biocryst Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.40%17.5M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Ra Capital Management, L.P. | 13G | 7.30%15.3M shares | New | Nov 12, 20251 filing | Nov 12, 2025 | SEC |
| Flynn James E | 13G | 5.80%12.2M shares | New | Sep 19, 20251 filing | Sep 19, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Biocryst Pharmaceuticals Inc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 20258:27 PM ET | Ra Capital Management, L.P.and 3 others | 13G | 7.30%15.3M shares | New | Nov 4, 2025 | SEC |
| Sep 19, 202512:23 PM ET | Flynn James Eand 3 others | 13G | 5.80%12.2M shares | New | Sep 12, 2025 | SEC |
| May 15, 20259:31 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 4.20%8.70M shares | –Below 5% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 8.40%17.5M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Biocryst Pharmaceuticals Inc shares.
No Form 144 notices for Biocryst Pharmaceuticals Inc are on file.